Cetuximab, a chimeric monoclonal IgG1 antibody directed against the EGFR, blocks binding of endogenous EGFR ligands, thus inhibiting function of the receptor, induces internalization of EGFR, and targets cytotoxic immune effector cells towards EGFR‐expressing tumour cells via antibody‐dependent cellular cytotoxicity [13]. The gene discussed is EGFR; the disease is neoplasm.